We are live on ! Find out more
VC

Vivo Capital Portfolio holdings

AUM $1.2B
1-Year Est. Return 911.44%
This Fund
S&P 500
This Quarter Est. Return
+13.81%
1 Year Est. Return
+911.44%
3 Year Est. Return
+7,373.93%
5 Year Est. Return
+10,475.15%
10 Year Est. Return
+136,503.27%
AUM
$2.23B
AUM Growth
-$82.9M
Cap. Flow
-$145M
Cap. Flow %
-6.5%
Top 10 Hldgs %
65.91%
Holding
64
New
5
Increased
3
Reduced
16
Closed
4

Top Buys

Rank Stock Value
1
WHWK
Whitehawk Therapeutics
WHWK
+$43.5M
2
SERA icon
Sera Prognostics
SERA
+$19.3M
3
VRDN icon
Viridian Therapeutics
VRDN
+$19.1M
4
DICE
DICE Therapeutics, Inc. Common Stock
DICE
+$14M
5
HRMY icon
Harmony Biosciences
HRMY
+$11.3M

Top Sells

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$105M
2
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$25.8M
3
CLDX icon
Celldex Therapeutics
CLDX
+$22.7M
4
LEGN icon
Legend Biotech
LEGN
+$19.5M
5
NVAX icon
Novavax
NVAX
+$18.7M

Sector Composition

Rank Sector Weight
1 Healthcare 85.61%
2 Financials 7.21%
3 Materials 7.18%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALXO icon
1
ALX Oncology
ALXO
$268M
$312M 14%
4,220,048
– –
TIL icon
2
Instil Bio
TIL
$49.4M
$223M 10.02%
624,339
– –
HRMY icon
3
Harmony Biosciences
HRMY
$2.07B
$187M 8.41%
4,884,341
+350,000
+8% +$11.3M
NFH
4
DELISTED
New Frontier Health Corporation Ordinary Shares
NFH
$161M 7.21%
14,300,000
– –
AMRS
5
DELISTED
Amyris Inc.
AMRS
$160M 7.18%
11,642,195
+2,266
+0% +$32.4K
ASND icon
6
Ascendis Pharma A/S
ASND
$16.7B
$121M 5.44%
760,606
-765,753
-50% -$105M
ISEE
7
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$96.9M 4.35%
5,966,527
– –
GTH
8
DELISTED
Genetron Holdings Limited ADS
GTH
$87.8M 3.94%
2,113,287
– –
TARS icon
9
Tarsus Pharmaceuticals
TARS
$2.57B
$64.4M 2.89%
2,987,331
– –
ALGS icon
10
Aligos Therapeutics
ALGS
$26.3M
$55M 2.47%
141,881
– –
BOLT icon
11
Bolt Biotherapeutics
BOLT
$7.72M
$49M 2.2%
193,565
– –
SRRA
12
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$42M 1.89%
1,917,074
– –
WHWK
13
Whitehawk Therapeutics
WHWK
$182M
$41.9M 1.88%
+1,427,213
New +$43.5M
SVA
14
DELISTED
Sinovac Biotech, Ltd
SVA
$38.2M 1.71%
5,900,000
– –
KDMN
15
DELISTED
Kadmon Holdings, Inc.
KDMN
$37.3M 1.68%
4,283,014
-1,534,445
-26% -$8.74M
IMPL
16
DELISTED
Impel Pharmaceuticals Inc. Common Stock
IMPL
$35.1M 1.58%
2,884,789
– –
OLMA icon
17
Olema Pharmaceuticals
OLMA
$1.01B
$34.1M 1.53%
1,238,575
– –
AVDL
18
DELISTED
Avadel Pharmaceuticals
AVDL
$28.8M 1.29%
2,937,093
– –
KALV
19
DELISTED
KalVista Pharmaceuticals
KALV
$28.7M 1.29%
1,641,913
-221,383
-12% -$4.49M
TERN
20
DELISTED
Terns Pharmaceuticals
TERN
$27.9M 1.25%
2,675,133
– –
CLDX icon
21
Celldex Therapeutics
CLDX
$2.79B
$26.2M 1.17%
484,453
-484,453
-50% -$22.7M
LEGN icon
22
Legend Biotech
LEGN
$3.68B
$24.7M 1.11%
488,751
-467,951
-49% -$19.5M
VRDN icon
23
Viridian Therapeutics
VRDN
$2.15B
$21.4M 0.96%
+1,300,000
New +$19.1M
SERA icon
24
Sera Prognostics
SERA
$79.5M
$20.6M 0.93%
+1,856,011
New +$19.3M
ZLAB icon
25
Zai Lab
ZLAB
$2.1B
$18.4M 0.83%
174,999
-1
-0% -$144
1
2 3

Similar funds

SGDR
SPX Gestao de Recursos Rio De Janeiro, Brazil $1.2B AUM 59.05% 1-Year Est. Return
FCCPG
FountainVest China Capital Partners GP3 Grand Cayman, Cayman Islands $1.2B AUM 6.95% 1-Year Est. Return
GP
Guardian Partners Toronto, Canada $1.2B AUM 35.94% 1-Year Est. Return
AIM
Anchor Investment Management Columbia, South Carolina $1.2B AUM 17.33% 1-Year Est. Return
CA
Callahan Advisors Houston, Texas $1.2B AUM 22.34% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
HCM
Hodges Capital Management Dallas, Texas $1.21B AUM 49% 1-Year Est. Return
MB
MidFirst Bank Oklahoma City, Oklahoma $1.21B AUM

Vivo Capital's Q3 2021 Portfolio in Review

As of Q3 2021, Vivo Capital held 64 positions worth $2.23B, down 3.6% from $2.31B the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Vivo Capital withdrew a net $145M in Q3 2021, closing 4 positions and reducing 16 holdings. Its most notable exit was Novavax, an estimated $18.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 85% a quarter earlier, followed by Financials and Materials.

Against the trend, Vivo Capital opened a new position in Whitehawk Therapeutics worth $41.9M.

  • Vivo Capital's largest Q3 2021 buy was Whitehawk Therapeutics: 1,427,213 shares worth $41.9M.
  • Vivo Capital added most to Harmony Biosciences in Q3 2021, an estimated $11.3M increase.
  • Vivo Capital's biggest Q3 2021 reduction was Ascendis Pharma A/S, cutting an estimated $105M.
  • Vivo Capital fully exited Novavax in Q3 2021, selling an estimated $18.7M.
  • Vivo Capital's ten largest holdings make up 66% of its $2.23B portfolio in Q3 2021.
  • Vivo Capital opened 5 new positions and closed 4 in Q3 2021.
  • Vivo Capital's portfolio value fell 3.6% quarter-over-quarter to $2.23B.

Based on Vivo Capital's 13F filing for Q3 2021, filed 15 Nov 2021.